Table of Contents

Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

What’s New in the Guidelines

Overview

• Overview of COVID-19
• Testing for SARS-CoV-2 Infection
• Prevention of SARS-CoV-2 Infection
• Clinical Spectrum of SARS-CoV-2 Infection
• Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment of COVID-19 in Nonhospitalized Patients When There Are Logistical Constraints

Clinical Management of Adults

• Clinical Management of Adults Summary
• General Management of Nonhospitalized Adults With Acute COVID-19
• Therapeutic Management of Nonhospitalized Adults With COVID-19
• Therapeutic Management of Hospitalized Adults With COVID-19

Clinical Management of Children

• Clinical Management of Children Summary
• Special Considerations in Children
• Therapeutic Management of Nonhospitalized Children With COVID-19
• Therapeutic Management of Hospitalized Children With COVID-19
• Therapeutic Management of Hospitalized Pediatric Patients With Multisystem Inflammatory Syndrome in Children (MIS-C) (With Discussion on Multisystem Inflammatory Syndrome in Adults [MIS-A])

Critical Care for Adults

• Care of Critically Ill Adults With COVID-19 (Summary Recommendations)
• Introduction to Critical Care Management of Adults With COVID-19
• Hemodynamics for Adults
• Oxygenation and Ventilation for Adults
• Pharmacologic Interventions for Critically Ill Patients
• Extracorporeal Membrane Oxygenation for Adults

Critical Care for Children

• Introduction to Critical Care Management of Children With COVID-19
• Hemodynamic Considerations for Children
• Oxygenation and Ventilation for Children
• Extracorporeal Membrane Oxygenation for Children

Antivirals, Including Antibody Products

• Antiviral Agents, Including Antibody Products (Summary Recommendations)
• Remdesivir
  • Table 4a. Remdesivir: Selected Clinical Data
• Ritonavir-Boosted Nirmatrelvir (Paxlovid)
  • Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
• Molnupiravir
• Anti-SARS-CoV-2 Monoclonal Antibodies
  • Table 4b. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
• COVID-19 Convalescent Plasma
  • Table 4c. COVID-19 Convalescent Plasma: Selected Clinical Data
• Interferons
  • Table 4d. Interferons: Selected Clinical Data
• Table 4e. Characteristics of Antiviral Agents, Including Antibody Products

Immunomodulators

• Immunomodulators (Summary Recommendations)
• Corticosteroids
  • Table 5a. Systemic Corticosteroids: Selected Clinical Data
  • Table 5b. Inhaled Corticosteroids: Selected Clinical Data
• Interleukin-6 Inhibitors
  • Table 5c. Interleukin-6 Inhibitors: Selected Clinical Data
• Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors
  • Table 5d. Kinase Inhibitors: Selected Clinical Data
• Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors
  • Table 5e. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
• Interleukin-1 Inhibitors
• Table 5f. Characteristics of Immunomodulators

Antithrombotic Therapy in Patients With COVID-19

• Table 6a. Anticoagulant Therapy: Selected Clinical Data
• Table 6b. Antiplatelet Therapy: Selected Clinical Data

Miscellaneous Drugs

• Miscellaneous Drugs (Summary Recommendations)
• Colchicine
• Fluvoxamine
  • Table 7a. Fluvoxamine: Selected Clinical Data
• Intravenous Immunoglobulin
• Ivermectin
  • Table 7b. Ivermectin: Selected Clinical Data
• Metformin
  • Table 7c. Metformin: Selected Clinical Data
• Table 7d. Characteristics of Miscellaneous Drugs

Supplements

• Supplements (Summary Recommendations)
• Vitamin C
• Vitamin D
• Zinc

Considerations for Using Concomitant Medications in Patients With COVID-19

Special Populations

• Special Considerations in People Who Are Immunocompromised
• Special Considerations in Adults and Children With Cancer
• Special Considerations in Solid Organ Transplant, Hematopoietic Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients
• Special Considerations During Pregnancy and After Delivery
• Influenza and COVID-19
• Special Considerations in People With HIV

Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members

Appendix A, Table 2. COVID-19 Treatment Guidelines Panel Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics